Zobrazeno 1 - 10
of 349
pro vyhledávání: '"Stefano Molica"'
Publikováno v:
Cancers, Vol 16, Iss 6, p 1085 (2024)
To assess the impact of first-line treatment with targeted agents (TAs) or fludarabine, cyclophosphamide, and rituximab (FCR)-based chemo-immunotherapy (CIT) on overall survival (OS) compared to age- and sex-matched individuals in the general populat
Externí odkaz:
https://doaj.org/article/7481d763564a406ca5a265c4c40abaab
Autor:
Francesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò, Carla Minoia, Roberta Murru, Paolo Sportoletti, Ferdinando Frigeri, Francesco Albano, Nicola Di Renzo, Alessandro Sanna, Luca Laurenti, Massimo Massaia, Ramona Cassin, Marta Coscia, Caterina Patti, Elsa Pennese, Agostino Tafuri, Annalisa Chiarenza, Piero Galieni, Omar Perbellini, Carmine Selleri, Catello Califano, Felicetto Ferrara, Antonio Cuneo, Marco Murineddu, Gaetano Palumbo, Ilaria Scortechini, Alessandra Tedeschi, Livio Trentin, Marzia Varettoni, Fabrizio Pane, Anna Marina Liberati, Francesco Merli, Lucia Morello, Gerardo Musuraca, Monica Tani, Adalberto Ibatici, Giulia Regazzoni, Michele Di Candia, Maria Palma, Danilo Arienti, Stefano Molica
Publikováno v:
Cancers, Vol 16, Iss 6, p 1228 (2024)
Real-world data in clinical practice are needed to confirm the efficacy and safety that ibrutinib has demonstrated in clinical trials of patients with chronic lymphocytic leukemia (CLL). We described the real-world persistence rate, patterns of use,
Externí odkaz:
https://doaj.org/article/af2f2bc5c0104fa9afc9c0f03049bca7
Autor:
Simone Oerlemans, Fabio Efficace, Omar Shamieh, Fabio Cardoso Borges, Corine De Jong, Dong Dong, Jens Lehmann, Sandra Malak, Duska Petranovic, Christian Scholz, Giovanni Caocci, Stefano Molica, Laimonas Griskevicius, Eva Nagele, Anne Bredart, Elisabete Carvalho, Aliki Xochelli, Joost Agelink van Rentergem, Waleed Alrjoob, Anja Mueller, Ana Carolina Freitas, Kim Cocks, Carien Creutzberg, Charalampia Kyriakou, Lonneke Van de Poll-Franse
Publikováno v:
HemaSphere, Vol 7, p e52692b6 (2023)
Externí odkaz:
https://doaj.org/article/c3f36cb5e4044209bc2ca8c4f6ac182c
Autor:
Matteo Molica, Salvatore Perrone, Vincenzo Federico, Caterina Alati, Stefano Molica, Marco Rossi
Publikováno v:
Cancers, Vol 16, Iss 1, p 73 (2023)
The combination approach based on venetoclax (VEN) with azacytidine (AZA) has significantly improved outcomes for elderly patients with acute myeloid leukemia (AML). This innovative approach has led to higher rates of overall response, measurable res
Externí odkaz:
https://doaj.org/article/75f1b2ebb2ae4aaca823f8cd755301d4
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Chronic lymphocytic leukaemia (CLL) is a malignancy of clonally expanded antigen-switched, neoplastic, mature B cells. CLL is characterised by a variable degree of immunosuppression and secondary hypogammaglobulinemia. B-cell depleting therapies have
Externí odkaz:
https://doaj.org/article/32fbe03366384be698cd924edc236c5a
Autor:
Andrea Visentin, Francesca Romana Mauro, Gioachino Catania, Alberto Fresa, Candida Vitale, Alessandro Sanna, Veronica Mattiello, Francesca Cibien, Paolo Sportoletti, Massimo Gentile, Gian Matteo Rigolin, Francesca Maria Quaglia, Roberta Murru, Alessandro Gozzetti, Stefano Molica, Monia Marchetti, Stefano Pravato, Francesco Angotzi, Alessandro Cellini, Lydia Scarfò, Gianluigi Reda, Marta Coscia, Luca Laurenti, Paolo Ghia, Robin Foà, Antonio Cuneo, Livio Trentin
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
One of the main issues in the treatment of patients with chronic lymphocytic leukemia (CLL) deals with the choice between continuous or fixed-duration therapy. Continuous ibrutinib (IB), the first-in-class BTK inhibitor, and obinutuzumab-chlorambucil
Externí odkaz:
https://doaj.org/article/26e89ef70eee4bd594a63aa05621a090
Publikováno v:
Cancers, Vol 15, Iss 14, p 3737 (2023)
Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL). The use of ibrutinib is, how
Externí odkaz:
https://doaj.org/article/ea35f309b2d44265a0a75a61488df275
Autor:
Luca Laurenti, Gianluca Gaidano, Francesca Romana Mauro, Stefano Molica, Patrizio Pasqualetti, Lydia Scarfò, Paolo Ghia
Publikováno v:
HemaSphere, Vol 6, Iss 9, p e771 (2022)
Several treatment options are available for chronic lymphocytic leukemia (CLL) and, for this reason, treatment choice can result challenging after introducing oral targeted agents. This study aims at comparing patients’ and hematologists’ prefere
Externí odkaz:
https://doaj.org/article/4d8b4e70d2b841e9b60e0783076e18e8
Autor:
Antonio Cuneo, Anthony R. Mato, Gian Matteo Rigolin, Alfonso Piciocchi, Massimo Gentile, Luca Laurenti, John N. Allan, John M. Pagel, Danielle M. Brander, Brian T. Hill, Allison Winter, Nicole Lamanna, Constantine S. Tam, Ryan Jacobs, Frederick Lansigan, Paul M. Barr, Mazyar Shadman, Alan P. Skarbnik, Jeffrey J. Pu, Alison R. Sehgal, Stephen J. Schuster, Nirav N. Shah, Chaitra S. Ujjani, Lindsey Roeker, Ester Maria Orlandi, Atto Billio, Livio Trentin, Martin Spacek, Monia Marchetti, Alessandra Tedeschi, Fiorella Ilariucci, Gianluca Gaidano, Michael Doubek, Lucia Farina, Stefano Molica, Francesco Di Raimondo, Marta Coscia, Francesca Romana Mauro, Javier de la Serna, Angeles Medina Perez, Isacco Ferrarini, Giuseppe Cimino, Maurizio Cavallari, Rosalba Cucci, Marco Vignetti, Robin Foà, Paolo Ghia, the GIMEMA, European Research Initiative (ERIC) on CLL, US study group
Publikováno v:
Cancer Medicine, Vol 9, Iss 22, Pp 8468-8479 (2020)
Abstract Limited information is available on the efficacy of front‐line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort of real‐world patie
Externí odkaz:
https://doaj.org/article/51d4f3af2edb4e18930e0b7ba14d8eff
Autor:
Stefano Molica, Paolo Sportoletti, Nicola Di Renzo, Pellegrino Musto, Fabrizio Pane, Francesco Di Raimondo
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 13, Iss 1 (2021)
With more than 3 million proven infections and 100.000 associated deaths in Italy, the COVID-19 pandemic poses extraordinary challenges to health-care professionals and especially to those caring for patients with haematologic malignancies (1-2). Giv
Externí odkaz:
https://doaj.org/article/8b865993864446f6bb19eb47e1dd631c